Thermo Fisher Scientific Announces $4.1 Billion Acquisition of Solventum’s Purification & Filtration Business

Feb 26, 2025 17:15 CST Updated 17:15

Thermo Fisher Scientific

Biotechnology Product Developer

Instrument Family

Pioneer in Medical Device Media Reports

Share Professional Medical Device Knowledge

Source:Instrument Family,Reproduction without authorization is prohibited, and reproduction is allowed 24 hours later.

Recently, Thermo Fisher Scientific announced a major acquisition plan. The companyThermo Fisher Scientific to Acquire Solventum's Purification and Filtration Business for $4.1 Billion in CashThis news has triggered strong attention in the capital market.

Data shows,SolventumSpin-off from 3M Company and independently listed last year, itsPurification and filtration businesses possess key technologies in the fields of medical technology, biotechnology, and industrial applications, providing crucial support for the production of related products.In 2024, the business generated approximately US$1 billion in revenue, demonstrating a strong market presence.Potential.

In early trading, its shares soared more than 8% due to the news, rising to $82.76 per share. As of the close on February 25 EST,Solventum's stock price rose by 9.54%, closing at $83.56 per share, with a total market capitalization of $14.436 billion.; while the share price of Thermo Fisher Scientific remained basically stable, closing at USD 539.55 per share on that day, with a total market value of USD 203.6 billion.

Solventum Sold for Nearly 30 BillionPurification and Filtration Business

It is reported that this timeSolventumThe sale is an important part of the third phase of the company's transformation plan. Through a comprehensive evaluation of business value and strategic fit,The company believes that this transaction will not only strengthen strategic priorities and key metrics but also effectively reduce leverage, significantly enhancing the robustness of the balance sheet.Will provide more resources for the company in innovation, project advancement, and talent cultivation, helping to fulfill the company's mission and create greater value for shareholders.

Company management plans to discuss the sale in detail during the earnings call on February 27.

Thermo Fisher Scientific believes that,SolventumThe purification and filtration business is highly complementary to its own bioproduction business. President and CEO Marc Casper pointed out,This acquisition is an excellent strategic move that will create significant value for customers and shareholders.SolventumThe combination of solutions will be highly recognized by customers, further highlighting the company's rigorous and effective capital allocation strategy, which has already brought substantial returns to shareholders in the past.

It is reported that,This transaction is expected to be completed by the end of 2025., but it is subject to customary closing conditions and regulatory approval. Once completed,SolventumThe purification and filtration business will be integrated into Thermo Fisher Scientific's Life Sciences Solutions segment.

Marc CasperAs a trusted partner of our customers,SolventumThe business will expand and enrich the company's bioprocessing product portfolio, enabling it to better serve customers in a rapidly growing market. The company looks forward to welcoming new colleagues to jointly drive business growth.

Split from a major medical device company

Public information shows that on April 1, 2024, 3M Company officially spun off its healthcare division (Health Care) to establish a new independent company, namelySolventum Healthcare。

BacktrackSolventumDevelopment History: In June 2022, industry giant 3M first signaled its intention to spin off its healthcare business as an independent entity. This news, like a stone thrown into a calm lake, caused ripples of widespread attention and discussion both within and outside the industry. On July 26 of the same year, 3M officially announced the spin-off of its medical sector business with the aim of achieving long-term sustainable growth and meeting the diverse needs of different businesses, paving the way for the birth of Solventum.

In November 2023, 3M announced that the independent healthcare company after the spin-off would be namedSolventum, this naming marks the new company's official entry into the public eye.，which also makes the industry full of expectations for its future development.

2024 is a pivotal year for Solventum's development. On February 21, 3M submitted a statement to the U.S. Securities and Exchange Commission, planning to spin off its healthcare business into Solventum on April 1.And listed on the New York Stock Exchange, a move that further advanced Solventum's independence process.In March, the 3M board approved the spin-off plan, giving the "green light" to the birth of Solventum.

On April 1, 2024, Solventum officially spun off from 3M, becoming an independent publicly listed company and was listed on the New York Stock Exchange with the stock code "SOLV". Its total market value reached $11.9 billion at the close of the first trading day, successfully making its mark in the capital market.

Four Main Business Segments of Solventum

Data shows that, in terms of business layout, Solventum continues the operations of 3M's healthcare division, covering four key segments: medical surgery, dental, health information systems, and filtration products.

Medical Surgery is Solventum's largest business unit, with a scale even surpassing the combined total of the other three divisions. This divisionFocused on providing a wide range of innovative advanced wound care and surgical solutions, with products ranging from stethoscopes to surgical equipment.The sales methods include both direct sales and distribution. In the advanced wound care market, 3M was once an undisputed leader, introducing well-known brands for negative pressure wound therapy and transparent film dressings, such as Tegaderm and Prevena. Previously, Solventum indicated that these devices still hold significant potential for market expansion.

Following medical surgery, dental services come next. Dental solutions provide comprehensive restorative, preventive, and orthodontic solutions.In terms of sales channels, Solventum not only has a direct sales network that includes dentists, orthodontists, group practices, universities, and more, but also collaborates with distributors to further expand its market coverage. In terms of products,Solventum, a leader in dental and orthodontic bonding solutions, has launched the first dental restorative composite material on the market and established well-known brands such as Filtek and Clarity.

The Health Information Systems segment is Solventum's third largest business unit,By providing software solutions through clinical intelligence, more time can be created for clinicians to care for patients, and the accuracy of healthcare reimbursement can be improved.This business is mainly divided into three major segments: clinical physician productivity solutions, revenue cycle management, and performance management solutions, among which revenue cycle...The sales contribution of the term management segment was the largest. Solventum stated that it is a leader in computer-assisted medical coding technology in the U.S. market, with more than 75% of American hospitals using at least one of its software solutions.

And the filtration business being sold this time,It is the segment with the smallest contribution to Solventum's performance (accounting for 12%), with revenue of $1 billion in 2023 (approximately 7.2 billion RMB). This business mainly provides filters and membranes used in the production of biopharmaceuticals, medical technology, microelectronics, food and beverage products, as well as for filtering cleaner drinking water.It is reported that, through innovative technology, Solventum has simplified the originally complicated three-step operation into one step and increased the process yield from 85% to 95%.

——

It is worth mentioning that after the independent spin-off and listing, Solventum's development has not been smooth. As an independent multinational company, it faces new market competition and challenges.In addition to facing huge debts, its cost control ability seems to have declined. In the latest financial report quarter released at the end of last year, its operating profit margin decreased by more than 10% compared with the same period last year.

For the quarter ended September 30 of last year, Solventum's adjusted net profit was $285 million, with sales reaching $2 billion.Compared to its performance as one of the four major divisions under 3M, its adjusted profit has plummeted by more than 40%.

In a severe development situation,In December last year, Solventum announced its restructuring and officially started layoffs.In the early morning of December 4, 2024, Solventum CEO Bryan Hanson conveyed a major decision regarding "layoffs" and "resource reallocation" to all employees through a video message. Immediately afterward, the company formally confirmed the layoff news to all employees via email. Subsequently,Solventum Confirms Layoff Plan to Multiple Media Outlets, Impacts to Extend Across Several Departments.

And this timeSolventumFor SalePurification and Filtration BusinessThe company believes that this transaction will not only strengthen strategic priorities and key metrics but also effectively reduce leverage, significantly enhancing the robustness of the balance sheet. So, what will the future hold? Acquired by Thermo Fisher ScientificPurification and Filtration BusinessLater, will it bring more opportunities for the company? Instrument Family Jiang will continue to follow up and report.

END

Philips "X-ray Tube Invention Patent Invalid Case" Loses Final Appeal

Johnson & Johnson's New Localization Achievement: "Made in China" HARMONIC® 7s Ultrasonic Scalpel Launched

Listed Device Company Lays Off Nearly All Employees

China's First: Acquisition of Japan's "Machine King" Top Business

Just now, the FDA urgently revoked the layoff notice

$11.4 Billion: Boston Scientific Makes a Big Move

"Acquisition Enthusiast" Acquires Neurointerventional Device Company

Buffett Sells $1 Billion, Giant Plummets 17%

"The Female Steve Jobs" Plans Next Venture from Prison

Top 10 ESG Companies in China's Medical Device Industry (Hong Kong Stock Exchange)

BusinessBusiness cooperation email: qxzj@landianyiliao.com